Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
cft1946 |CAS 2882165-79-7|DC Chemicals
CFT1946 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
CFT1946
CFT1946 is the first targeted protein degrader to enter clinical trial ...
CFT1946 Is an Orally Available Brain-Penetrant BRAF-Mutant Degrader ...
Tagarafdeg | CFT1946 | 选择性和可口服的突变型BRAF降解剂 | 抗增殖 | TargetMol
Cft1946 – Application in Therapy and Current Clinical Research
CFT1946 + Trametinib for Solid Tumors Clinical Trial 2024 | Power
CFT1946 An oral, mutant-selective BRAFV600X degrader In phase 1 trials ...
Abstract 2158: Preclinical evaluation of CFT1946 as a selective ...
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy
Tagarafdeg (CFT1946) | BRAFV600E Degrader | MedChemExpress
Tagarafdeg (CFT1946) | mutant BRAF PROTAC | Probechem Biochemicals
靶向SMARCA2 FIC 降解剂CFT1946首次公布 I 期临床结果：BRAF V600X实体瘤新疗法持续研究中 - 知乎
降解剂“竞技”AACR 2023年美国癌症研究协会年会（2023 AACR）刚刚落幕，作为主要聚焦肿瘤早期研究和基础创新的全球盛会，AACR ...
蛋白降解剂新篇章：2023年6大创新靶点临床进展深度解析（下） - 知乎
cccc-20240111
CFT1946, 2882165-79-7 | BroadPharm
Whole exome and whole transcriptome sequencing in melanoma patients to ...
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative ...
#cft1946 #brafv600einhibitors #bidacdegraders #protacs #buildingblocks ...
医药魔方
Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific ...
Mechanism of action of CFT1946, a novel BiDAC degrader, for mutant BRAF ...
Abstract 3425: The discovery and characterization of CFT1946: A potent ...
612O Preliminary results from a phase I study of CFT1946, a novel BIDAC ...
蛋白降解剂新篇章：2023年6大创新靶点临床进展深度解析（下） 商务要闻 | 华源医药网
#brafv600_mutant_degrader #cft1946 #phase1_trial | Vinayak Khairnar
Degraders | BroadPhar | BroadPharm
CFT-1946 - Drug Targets, Indications, Patents - Synapse
Cathy Eng's highlights from ESMO24 - OncoDaily
Cancer Research | American Association for Cancer Research
🩺 #Oncología| Los resultados preliminares del ensayo fase 1 del fármaco ...
C4T, ‘BRAF TPD’도 “중단”..MM ‘IKZF1/3’에 ‘집중’ - 바이오스펙테이터
After Restructuring, C4 Turns the Page on Its Targeted Protein Degrader ...
The med chem story behind C4 Therapeutics, Inc. was one of the ...
Ingo Hartung on Twitter: "Lots of stuff on my #AACR23 agenda. But what ...
融资又大涨！PROTACs新兴公司管线布局详览医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Targeting All BRAF Alterations: The (Re)-Search Continues | JCO ...
三款 「first-in-class」PROTAC ，首次公布临床结果
Excited to be working on this project! | Charles Kammerer
2022 AACR总结：最值得关注的小分子药物研发方向TOP10 2022年美国癌症研究协会（AACR）已然落幕，作为全球历史最悠久、规模最大 ...
【2023AACR】Braf靶向耐药问题有了新希望 - 知乎
Protein Degraders vs. Traditional Small Molecule Drugs
#colorectal #melanoma #nsclc #esmo24 | C4 Therapeutics, Inc.
So proud of our amazing team that represented C4T at ESMO! | Mary Christian
C4 Therapeutics: TORPEDO Platform Promising, Valuation Stretched ...
砖家预测： 2024 年可能被 FDA 批准上市 PROTAC 热门分子 - 知乎
Development of a potent small‐molecule degrader against oncogenic ...
2023 AACR：靶向蛋白降解剂的最新研究进展|多发性骨髓瘤|AACR|CDK4|降解剂|BTK|抑制剂|蛋白质|MYC|肿瘤|药物|-健康界
PROTAC BRAF-V600E degrader-2 | PROTAC BRAF-V600E Degrader | MedChemExpress
AACR速递丨蛋白降解剂最新进展汇总 - 知乎
2023AACR | 首次公开新药结构点评_药智新闻
C4 Therapeutics, Inc. (C4医药公司): 药物管线_专利_临床试验_投融营收_最新药物:CFT-7455，CFT1946 ...
#esmo24 | C4 Therapeutics, Inc.
slide6
Discovery of Selective Small Molecule Degraders of BRAF-V600E | Journal ...
slide4
CFT-8919 - Drug Targets, Indications, Patents - Synapse
#esmo24 #colorectal #melanoma #tpd | C4 Therapeutics, Inc.
C4 Therapeutics, Inc. on LinkedIn: #colorectalcancer # ...
CST 905 Supplier | CST905 | Tocris Bioscience
PROTACs currently in clinical trials. Data from clinicaltrials.gov ...
C4T halts BRAF degrader work to save cash for cemsidomide
C4 Therapeutics宣布裁员30%，重点推进3项降解剂临床试验医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
MK-0616
PROTAC BRAF-V600E degrader-1 | C48H54F2N10O10S | CID 146161288 - PubChem
slide5
蛋白降解剂新篇章：2023年6大创新靶点临床进展深度解析（下） 来源：药智头条公众号图片来源：摄图网2001年，雷蒙德·J·德赫斯教授与 ...
#aacr23 | C4 Therapeutics, Inc.
3万字长文梳理！PROTAC四大龙头公司医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
slide8
,%20ATC,%20CRC:%0A%0ACFT1946%20+%20Trametinib%20for%20Solid%20Tumors.png?md=1)
